Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Autor: Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, Rebekah Pennington, Barry Hounsome, Ellen Lever, Andrew Metry, Edith Poku, Yit Yang, Simon P Harding, Andrew Lotery, Usha Chakravarthy, John Brazier

Publikováno v: Health Technology Assessment, Vol 25, Iss 38 (2021)

Background: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Ro

Externí odkaz: https://doaj.org/article/e5f5366ffc58403b87cc8c40698ab4e5

Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis

Autor: Matt Stevenson, Andrew Metry, Michael Messenger

Publikováno v: Health Technology Assessment, Vol 25, Iss 21 (2021)

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019. At the time of writing (October 2020), the number of cases of COVID-19 had been approaching 38 million and more than 1 million

Externí odkaz: https://doaj.org/article/87a60384acd54c5fb62fed55a25dcdbe

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

Autor: Becky Pennington, Andrew Metry, Edith Poku, Joana C. Vasconcelos, Caroline Murphy, Sobha Sivaprasad, John Brazier, Philip G Hykin, Joanna Kelly, Andrew J. Lotery, A Toby Prevost, Abualbishr Alshreef, Yit C. Yang, Michael Williams, Laura Flight

Publikováno v: Pennington, B, Alshreef, A, Flight, L, Metry, A, Poku, E, Hykin, P, Sivaprasad, S, Prevost, A T, Vasconcelos, J C, Murphy, C, Kelly, J, Yang, Y, Lotery, A, Williams, M & Brazier, J 2021, ' Cost effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study ', PharmacoEconomics, vol. 39, no. 8, pp. 913–927 . https://doi.org/10.1007/s40273-021-01026-5
Pharmacoeconomics

Background We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. Methods We calculated costs and qual

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f4ebebeaf218c3f06bcc4fab3966179
https://doi.org/10.1007/s40273-021-01026-5

Jointly modelling economics and epidemiology to support public policy decisions for the COVID-19 response : a review of UK studies

Autor: Simon Walker, Mark Sculpher, Jasmina Panovska-Griffiths, Ruth Wong, Ana Duarte, Andrew Metry

Publikováno v: Pharmacoeconomics

COVID-19 in the UK has had a profound impact on population health and other socially important outcomes, including on education and the economy. Although a range of evidence has guided policy, epidemiological models have been central. It is less clea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81fb84f25f6a10f2af1a415a0a3a4ab5
https://eprints.whiterose.ac.uk/174341/3/COVID_modelling_paper_post_review.docx

Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis

Autor: Michael P. Messenger, Mark Stevenson, Andrew Metry

Publikováno v: Health Technology Assessment, Vol 25, Iss 39 (2021)
Health Technol Assess

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19), which at the time of writing (January 2021) was responsible for more than 2.25 million deaths worldwide and over 100,000 deaths

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecae2fc2a0892815ec78c6c30068aa31
https://doaj.org/article/b56b60f882a5485da70c86cb151c44ac